Oxford tests JnJ/Bavarian Nordic prime-boost Ebola vaccine
This article was originally published in Scrip
Executive Summary
Researchers at the University of Oxford have initiated a Phase I trial to test the safety and tolerability of an experimental prime-boost Ebola vaccine from Johnson & Johnson and its partner Bavarian Nordic.